vs
GREENLIGHT CAPITAL RE, LTD.（GLRE）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是GREENLIGHT CAPITAL RE, LTD.的1.0倍（$219.9M vs $210.3M），GREENLIGHT CAPITAL RE, LTD.净利率更高（23.4% vs -1.0%，领先24.4%），GREENLIGHT CAPITAL RE, LTD.同比增速更快（48.3% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.8%）
绿光资本再保险有限公司关联的绿光资本是1996年由大卫·艾因霍恩创立的美国对冲基金，主要投资北美公开交易的企业债务产品与股票，因2008年雷曼兄弟破产前做空其股票、2012年1月在英国因内幕交易被罚1100万美元而受到市场关注，艾因霍恩至今仍担任该基金管理人。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GLRE vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$210.3M
营收增速更快
GLRE
高出46.3%
2.0%
净利率更高
GLRE
高出24.4%
-1.0%
两年增速更快
OFIX
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $210.3M | $219.9M |
| 净利润 | $49.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 23.4% | -1.0% |
| 营收同比 | 48.3% | 2.0% |
| 净利润同比 | 279.7% | 92.4% |
| 每股收益（稀释后） | $1.43 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GLREOFIX
| Q4 25 | $210.3M | $219.9M | ||
| Q3 25 | $146.1M | $205.6M | ||
| Q2 25 | $160.1M | $203.1M | ||
| Q1 25 | $213.3M | $193.6M | ||
| Q4 24 | $141.8M | $215.7M | ||
| Q3 24 | $188.0M | $196.6M | ||
| Q2 24 | $174.9M | $198.6M | ||
| Q1 24 | $191.3M | $188.6M |
净利润GLREOFIX
| Q4 25 | $49.3M | $-2.2M | ||
| Q3 25 | $-4.4M | $-22.8M | ||
| Q2 25 | $329.0K | $-14.1M | ||
| Q1 25 | $29.6M | $-53.1M | ||
| Q4 24 | $-27.4M | $-29.1M | ||
| Q3 24 | $35.2M | $-27.4M | ||
| Q2 24 | $8.0M | $-33.4M | ||
| Q1 24 | $27.0M | $-36.0M |
毛利率GLREOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率GLREOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率GLREOFIX
| Q4 25 | 23.4% | -1.0% | ||
| Q3 25 | -3.0% | -11.1% | ||
| Q2 25 | 0.2% | -6.9% | ||
| Q1 25 | 13.9% | -27.4% | ||
| Q4 24 | -19.3% | -13.5% | ||
| Q3 24 | 18.7% | -13.9% | ||
| Q2 24 | 4.6% | -16.8% | ||
| Q1 24 | 14.1% | -19.1% |
每股收益（稀释后）GLREOFIX
| Q4 25 | $1.43 | $-0.05 | ||
| Q3 25 | $-0.13 | $-0.57 | ||
| Q2 25 | $0.01 | $-0.36 | ||
| Q1 25 | $0.86 | $-1.35 | ||
| Q4 24 | $-0.78 | $-0.76 | ||
| Q3 24 | $1.01 | $-0.71 | ||
| Q2 24 | $0.23 | $-0.88 | ||
| Q1 24 | $0.78 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.8M | $82.0M |
| 总债务越低越好 | $4.7M | — |
| 股东权益账面价值 | $708.0M | $450.0M |
| 总资产 | $2.2B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资GLREOFIX
| Q4 25 | $111.8M | $82.0M | ||
| Q3 25 | $68.8M | $62.9M | ||
| Q2 25 | $82.4M | $65.6M | ||
| Q1 25 | $47.5M | $58.0M | ||
| Q4 24 | $64.7M | $83.2M | ||
| Q3 24 | $54.6M | $30.1M | ||
| Q2 24 | $52.2M | $26.4M | ||
| Q1 24 | $61.6M | $27.0M |
总债务GLREOFIX
| Q4 25 | $4.7M | — | ||
| Q3 25 | $34.7M | $157.2M | ||
| Q2 25 | $58.9M | $157.0M | ||
| Q1 25 | $59.8M | $156.9M | ||
| Q4 24 | $60.7M | $157.0M | ||
| Q3 24 | $62.6M | $118.5M | ||
| Q2 24 | $61.6M | $118.0M | ||
| Q1 24 | $72.5M | $118.2M |
股东权益GLREOFIX
| Q4 25 | $708.0M | $450.0M | ||
| Q3 25 | $658.9M | $442.5M | ||
| Q2 25 | $663.3M | $458.3M | ||
| Q1 25 | $666.8M | $458.3M | ||
| Q4 24 | $635.9M | $503.1M | ||
| Q3 24 | $663.4M | $525.9M | ||
| Q2 24 | $634.0M | $546.0M | ||
| Q1 24 | $624.5M | $570.3M |
总资产GLREOFIX
| Q4 25 | $2.2B | $850.6M | ||
| Q3 25 | $2.1B | $832.6M | ||
| Q2 25 | $2.2B | $837.2M | ||
| Q1 25 | $2.2B | $823.1M | ||
| Q4 24 | $2.0B | $893.3M | ||
| Q3 24 | $2.0B | $867.9M | ||
| Q2 24 | $1.9B | $882.0M | ||
| Q1 24 | $1.9B | $906.0M |
负债/权益比GLREOFIX
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.05× | 0.36× | ||
| Q2 25 | 0.09× | 0.34× | ||
| Q1 25 | 0.09× | 0.34× | ||
| Q4 24 | 0.10× | 0.31× | ||
| Q3 24 | 0.09× | 0.23× | ||
| Q2 24 | 0.10× | 0.22× | ||
| Q1 24 | 0.12× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $100.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | 2.03× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GLREOFIX
| Q4 25 | $100.2M | $27.7M | ||
| Q3 25 | $31.2M | $12.4M | ||
| Q2 25 | $68.4M | $11.6M | ||
| Q1 25 | $10.4M | $-18.4M | ||
| Q4 24 | $29.5M | $23.7M | ||
| Q3 24 | $41.3M | $11.7M | ||
| Q2 24 | $22.7M | $9.0M | ||
| Q1 24 | $18.0M | $-18.6M |
自由现金流GLREOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率GLREOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度GLREOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率GLREOFIX
| Q4 25 | 2.03× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 208.02× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 0.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GLRE
| Other | $124.7M | 59% |
| Innovations | $85.6M | 41% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
